{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "go:GO:0006915",
      "entity_text" : "apoptosis",
      "entity_type" : "bioprocess"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "interpro:IPR001314",
      "entity_text" : "chymotrypsin",
      "entity_type" : "family"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Bortezomib (LDP-341, MG-341, MLN-341, PS-341, Velcade) is a dipeptide boronic acid that reversibly inhibits the chymotrypsin like proteolytic activity site of the 20S proteasome, which induces apoptosis, reverses drug resistance in multiple myeloma cells, and which influences their microenvironment by blocking cytokine circuits, cell adhesion, and angiogenesis in vivo.",
  "reading_complete" : "2020-08-05T22:29:13Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-05T22:25:20Z",
  "trigger" : "induces",
  "evidence" : [ "chymotrypsin-like proteolytic activity site of the 20S proteasome              , which induces apoptosis" ],
  "pmc_id" : "3321668",
  "score" : 0
}